Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Mar 02, 2022 3:47pm
122 Views
Post# 34476449

RE:RE:RE:Talking Down Good News

RE:RE:RE:Talking Down Good NewsIm not that Farmer .. neither pumping/ bashing , 
after 5 years invested here and not farther ahead on the development  than  2017 , forgive me if at times I question the companies motives , I've learned to sale any heights and buy the lows in the hope that one day , We can truly be rewarded .. keep  in mind   ( March 2021)   Debenture Terms
The Debentures are convertible into ProMIS common shares at the option of the holder at a conversion price of US$0.10 per share and accrue interest at 1% per annum, which is payable annually. At the company’s election, accrued interest may be paid in cash or common shares (such number of shares determined by dividing the interest due by the 5-day volume-weighted average trading price or “VWAP” of the common shares).

quote=bball67]Farmer John aka Mr Mole, talking down a stock, saying it is recyled news and that there is nothing here is an extremely negative interpretation. I had been questionning whether you were really bullish on this stock. Now I know your true orientation. You have incredible disdain for the Company. This is NOT the the in vivo test done 3-4 years ago. You can be of the opinion that it means nothing. I disagree.[/quote]

<< Previous
Bullboard Posts
Next >>